Quality control of MHC class II associated peptides by HLA-DM/H2-M

Seminars in Immunology

Volumn 11, Issue 6, 1999, Pages 391-403

  Vogt, Anne B ^a   Kropshofer, Harald ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Antigen presentation; Chaperone; Editing; H2 M; HLA DM; MHc class II

Indexed keywords

CHAPERONE; H2 ANTIGEN; HLA DM ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN PRESENTATION; REVIEW;

EID: 0343049067     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1006/smim.1999.0197     Document Type: Article

References (102)

1. Wolf PR, Ploegh HL. How MHC class II molecules acquire peptide charge: biosynthesis and trafficking through the endocytic pathway. Ann Rev Cell Dev Biol. 11:1995;267-306.
2. Busch R, Mellins ED. Developing and shedding inhibitions: how MHC class II molecules reach maturity. Curr Opin Immunol. 8:1996;51-58.
3. +T cell selection in mice lacking invariant chain expression. J Exp Med. 177:1993;1699-1712.
4. Viville S, Neefjes J, Lotteau V, Dierich A, Lemeur M, Ploegh H, Benoist C, Mathis D. Mice lacking the MHC class II-associated invariant chain. Cell. 72:1993;635-648.
5. Bonnerot C, Marks MS, Cosson P, Robertson EJ, Bikoff EK, Germain RN, Bonifacino JS. Association with BiP and aggregation of class II MHC molecules synthesized in the absence of invariant chain. EMBO J. 13:1994;934-944.
6. Bakke O, Dobberstein B. MHC class II-associated invariant chain contains a sorting signal for endosomal compartments. Cell. 63:1990;707-715.
7. Lotteau V, Teyton L, Peleraux A, Nilsson T, Karlsson L, Schmid SL, Qu aranta V, Peterson PA. Intracellular transport of class II MHC molecules directed by the invariant chain. Nature. 348:1990;600-605.
8. Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature. 360:1992;474-477.
9. Romagnoli P, Germain RN. The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy. J Exp Med. 180:1994;1107-1113.
10. Vogt AB, Kropshofer H, Hämmerling GJ. How HLA-DM affects the peptide repertoire bound to HLA-DR molecules. Human Immunol. 54:1997;170-179.
11. Mellins E, Smith L, Arp B, Cotner T, Celis E, Pious D. Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes. Nature. 343:1990;71-74.
12. Ceman S, Rudersdorf R, Long EO, Demars R. MHC class II deletion mutant expresses normal levels of transgene encoded class II molecules that have abnormal conformation and impaired antigen presentation ability. J Immunol. 149:1992;754-761.
13. Sette A, Ceman S, Kubo RT, Sakaguchi K, Appella E, Hunt DF, Davis TA, Michel H, Shabanowitz J, Rudersdorf R, Grey HM, DeMars R. Invariant chain peptides in most HLA-DR molecules of an antigen processing mutant. Science. 258:1992;1801-1804.
14. Monji T, McCormack AL, Yates III JR, Pious D. Invariant-cognate peptide exchange restores class II dimer stability in HLA-DM-mutants. J Immunol. 153:1994;4468-4477.
15. Avva R, Cresswell P. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity. 1:1994;763-774.
16. Kropshofer H, Vogt AB, Stern LJ, Hämmerling GJ. Self-release of CLIP in peptide loading of HLA-DR molecules. Science. 270:1995;1357-1359.
17. Urban RG, Chicz RM, Strominger JL. Selective release of some invariant chain-derived peptides from HLA-DR1 molecules at endosomal pH. J Exp Med. 180:1994;751-755.
18. Kropshofer H, Vogt AB, Hämmerling GJ. Structural features of invariant chain CLIP region controlling rapid release from HLA-DR molecules and inhibition of peptide binding. Proc Nati Acad Sci USA. 92:1995;8313-8317.
19. Adams S, Humphreys RE. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules. Eur J Immunol. 25:1995;1693-1702.
20. Ma C, Blum JS. Receptor-mediated endocytosis of antigens overcomes the requirement for HLA-DM in class ll-restricted antigen presentation. J Immunol. 158:1997;1-4.
21. Brooks AG, Campbell PL, Reynolds P, Gautam AM, McCluskey J. Antigen presentation and assembly by mouse I-Ak class II molecules in human APC containing deleted or mutated HLA-DM genes. J Immunol. 153:1994;5382-5392.
22. Stebbins CS, Loss Jr GE, Elias CG, Chervonsky A, Sant AJ. The requirement for DM in class II restricted antigen presentation and SDS-stable dimer formation is allele and species dependent. J Exp Med. 181:1995;223-234.
23. Sette A, Southwood S, Miller J, Appella E. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J Exp Med. 181:1995;677-683.
24. Morris P, Shaman J, Attaya M, Amaya M, Goodman S, Bergman C, Monaco JJ, Mellins E. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature. 368:1994;551-554.
25. Fling SP, Arp B, Pious D. The HLA-DMA gene is required for the formation of stable class II/peptide complexes. Nature. 368:1994;554-558.
26. Denzin LK, Robbins NF, Carboy-Newcomb C, Cresswell P. Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells. Immunity. 1:1994;595-606.
27. Kelly AP, Monaco JJ, Cho S, Trowsdale J. A new human HLA class II-related locus. Nature. 353:1991;571-573.
28. Cho S, Attaya M, Monaco JJ. New class ll-like genes in the murine MHC. Nature. 353:1991;573-576.
29. Sanderson F, Kleijmeer M, Kelly A, Verwoerd D, Tulp A, Neefjes J, Geuze HJ, Trowsdale J. Accumulation of HLA-DM, a regulator of antigen presentation, in MHC class II compartments. Science. 266:1994;1566-1569.
30. Karlsson L, Peleraux A, Lindstedt R, Lijedahl M, Peterson PA. Reconstitution of an operational MHC class II compartment in nonantigen presenting cells. Science. 266:1994;1569-1572.
31. Peters PJ, Neefjes JJ, Oorschot V, Ploegh HL, Geuze HJ. Segregation of MHC class II molecules from MHC class I molecules in the Golgi complex for transport to lysosomal compartments. Nature. 349:1991;669-676.
32. Marks MS, Roche PA, van Donselaar E, Woodruff L, Peters PJ, Bonifacino JS. A lysosomal targeting signal in the cytoplasmic tail of the β chain directs HLA-DM to MHC class II compartments. J Cell Biol. 131:1995;351-369.
33. Lindstedt R, Lijedahl M, Péléraux A, Peterson PA, Karlsson L. The MHC class II molecule H2-M is targeted to an endosomal compartment by a tyrosine based targeting motif. Immunity. 3:1995;561-572.
34. Sanderson F, Powis SH, Kelly AP, Trowsdale J. Limited polymorphism in HLA-DM does not involve the peptide binding groove. Immunogenetics. 39:1994;56-58.
35. Kropshofer H, Arndt SO, Moldenhauer G, Hämmerling GJ, Vogt AB. HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity. 6:1997;293-302.
36. Mosyak L, Zaller DM, Wiley DC. The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation. Immunity. 9:1998;377-383.
37. Fremont DH, Crawford F, Marrack P, Hendrickson WA, Kappler J. Crystal structure of mouse H2-M. Immunity. 9:1998;385-393.
38. Sloan VS, Cameron P, Porter G, Gammon M, Amaya M, Mellins E, Zaller DM. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature. 375:1995;802-806.
39. Sherman MA, Weber DA, Jensen P. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptides. Immunity. 3:1995;197-205.
40. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class II αβ dimers and facilitates peptide loading. Cell. 82:1995;155-165.
41. Buus S, Sette A, Colon SM, Jenis DM, Grey HM. Isolation and characterization of antigen-Ia complexes involved in T cell recognition. Cell. 47:1986;1071-1077.
42. Vogt AB, Kropshofer H, Moldenhauer G, Hämmerling GJ. Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM. Proc Natl Acad Sci USA. 93:1996;9724-9729.
43. Flynn GC, Chappell TG, Rothman JE. Peptide binding and release by proteins implicated as catalysts of protein assembly. Science. 245:1989;385-390.
44. Lyles MM, Gilbert HF. Catalysis of the oxidative folding of ribonuclease A by protein disulfide isomerase: dependence of the rate on the composition of the redox buffer. Biochemistry. 30:1991;613-619.
45. Sanderson F, Thomas C, Neefjes J, Trowsdale J. Association between HLA-DM and HLA-DR in vivo. Immunity. 4:1996;87-96.
46. Runnels HA, Moore JC, Jensen PE. A structural transition in class II major histocompatibility complex proteins ad mildly acidic pH. J Exp Med. 183:1996;127-136.
47. Boniface JJ, Lyons DS, Wettstein DA, Allbritton NL, Davis MM. Evidence for a conformational change in a class II major histocompatibility complex molecule occurring in the same pH range where antigen binding is enhanced. J Exp Med. 183:1996;119-126.
48. Ullrich HJ, Doring K, Gruneberg U, Jahnig F, Trowsdale J, van Ham SM. Interaction between HLA-DM and HLA-DR involves regions that undergo conformation and changes at lysosomal pH. Proc Nati Acad Sci USA. 94:1997;13163-13168.
49. Sadegh-Nasseri S, Germain RN. A role for peptide in determining MHC class II structure. Nature. 353:1991;167-170.
50. Stern LJ, Wiley DC. The human MHC class II protein HLA-DR1 assembles as empty αβ-heterodimers in the absence of antigenic peptide. Cell. 68:1992;465-477.
51. Germain R, Rinker Jr AG. Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes selective cell surface expression of occupied molecules. Nature. 363:1993;725-728.
52. Sadegh-Nasseri S, Stern LJ, Wiley DC, Germain RN. MHC class II function preserved by low-affinity peptide interactions preceding stable binding. Nature. 370:1994;647-650.
53. Denzin LK, Hammond C, Cresswell P. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J Exp Med. 184:1996;2153-2165.
54. Devaux B, Wilson KJ, Aguilar B, Jorgensen B, Rothbard JB. Differential stability of HLA-DR alleles independent of endogenous peptides. J Immunol. 155:1995;1921-1928.
55. Schafer PH, Green JM, Malapati S, Gu L, Pierce SK. HLA-DM is present in one-fifth the amount of HLA.DR in the class II peptide loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes. J Immunol. 157:1996;5487-5495.
56. Germain R, Hendrix LR. MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding. Nature. 353:1991;134-139.
57. Ellis RJ, van der Vies SM. Molecular chaperones. Annu Rev Biochem. 60:1991;321-347.
58. Ghosh P, Amaya M, Mellins E, Wiley DC. The structure of HLA-DR3 complexed with CLIP, an intermediate in peptide loading. Nature. 387:1995;457-462.
59. Roche PA. HLA-DM: an in vivo facilitator of MHC class II peptide loading. Immunity. 3:1995;259-262.
60. Kropshofer H, Hämmerling GJ, Vogt AB. How HLA-DM edits the MHC class II peptide repertoire: survival of the fittest? Immunol Today. 18:1997;77-82.
61. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, Wiley DC. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature. 368:1994;215-221.
62. Dornmair K, Rothenhäusler B, McConnell HM. Structural intermediates in the reactions of antigenic peptides with MHC molecules. Cold Spring Harbor Symp Quant Biol. 54:1989;409-416.
63. Vogt AB, Stern LJ, Amshoff C, Dobberstein B, Hämmerling GJ, Kropshofer H. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR. J Immunol. 155:1995;4757-4765.
64. Weber DA, Evavold BD, Jensen PE. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science. 274:1996;618-620.
65. Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, Hämmerling GJ. Editing of the HLA-DR peptide repertoire by HLA-DM. EMBO J. 15:1996;6144-6154.
66. van Ham SM, Grüneberg U, Malcharek G, Bröker I, Melms A, Trowsdale J. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs. J Exp Med. 184:1996;2019-2024.
67. Radrizzani L, Bono E, Vogt AB, Kropshofer H, Gallazzi F, Sturniolo T, Hämmerling GJ, Sinigaglia F, Hammer J. Identification of destabilizing residues in HLA class ll-selected bacteriophage display libraries edited by HLA-DM. Eur J Immunol. 29:1999;660-668.
68. Lanzavecchia A, Reid PA, Watts C. Irreversible association of p eptides with class II MHC molecules in living cells. Nature. 357:1992;249-252.
69. Busch R, Strang G, Howland K, Rothbard J. Degenerate binding of immunogenic peptides to HLA-DR proteins on B cells surfaces. Int Immunol. 2:1990;443-451.
70. Hammer J, Belunis C, Bolin D, Papadopoulos J, Walsky R, Higelin J, Danho W, Sinigaglia F, Nagy Z. High-affinity binding of short peptides to major histocompatibility complex class II molecules by anchor combinations. Proc Nati Acad Sci USA. 91:1994;4456-4460.
71. Chicz RM, Urban RG, Gorga JC, Vignali DAA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med. 178:1993;27-47.
72. Rammensee HG, Friede T, Stefanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics. 41:1995;178-228.
73. Vogt AB, Kropshofer H, Kalbacher H, Kalbus M, Rammensee HG, Coligan JE, Martin R. Ligand motifs of HLA-DRB5*01101 and DRB1*1501 molecules delineated from self-peptides. J Immunol. 153:1994;1665-1673.
74. Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ, Vignali DAA, Strominger JL. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature. 358:1992;764-768.
75. Katz JF, Stebbins C, Appella E, Sant AJ. Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules. J Exp Med. 184:1996;1747-1753.
76. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol. 10:1992;153-187.
77. Vergelli M, Pinet V, Vogt AB, Kalbus M, Malnati M, Riccio P, Long EO, Martin R. HLA-DR restricted presentation of purified myelin basic protein is independent of intracellular processing. Eur J Immunol. 27:1997;941-951.
78. Martin R, Howell MD, Jaraquemada D, Flerlage M, Richert J, Brostoff S, Long EO, McFarlin DE, McFarland HF. A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J Exp Med. 173:1991;19-24.
79. Miyazaki T, Wolf P, Tourne C, Waltzinger C, Dierich A, Barois N, Ploegh H, Benoist C, Mathis D. Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway. Cell. 84:1996;531-542.
80. Martin WD, Hicks GG, Mendiratta SK, Leva HI, Ruley HE, van Kaer L. H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection. Cell. 84:1996;543-550.
81. Fung-Leung W-P, Surh CD, Liljedahl M, Pang J, Leturcq D, Peterson PA, Webb SR, Karlsson L. Antigen presentation and T cell development in H2-M deficient mice. Science. 271:1996;1278-1281.
82. Wolf PR, Tourne S, Miyazaki T, Benoist C, Mathis D, Ploegh HL. The phenotype of the H-2M-deficient mice is dependent on the MHC class II molecules expressed. Eur J Immunol. 28:1998;2605-2618.
83. Kovats S, Grubin CE, Eastman E, deRoos P, Dongre A, Van Kaer L, Ruden sky AY. Invariant chain-independent function of H-2M in the formation of endogenous peptide-major histocompatibility complex class II complexes in vivo. J Exp Med. 187:1998;245-251.
84. Tourne S, Miyazaki T, Wolf P, Ploegh H, Benoist C, Mathis D. Fu nctionality of major histocompatibility complex class II molecules in mice doubl y deficient for invariant chain and H-2M complexes. Proc Natl Acad Sci USA. 94:1997;9255-9260.
85. Swier K, Brown DR, Bird JJ, Martin DW, Van Kaer L, Reiner SL. A critical, invariant chain independent role for H2-M in antigen presentation. J Immunol. 160:1998;540-544.
86. Tonelle C, DeMars R, Long EO. DOβ: a new β chain gene in HLA-D with a distinct regulation of expression. EMBO J. 4:1985;2839-2847.
87. Trowsdale J, Kelly A. The human HLA class II alpha chain gene DZ alpha is distinct from gene in the DP, DQ and DR subregions. EMBO J. 4:1985;2231-2237.
88. Liljedahl M, Kuwana T, Fung-Leung W-P, Jackson MR, Peterson PA, Karlsson L. HLA-DO is a lysosomal resident which requires association with HLA- DM for efficient intracellular transport. EMBO J. 15:1996;4817-4824.
89. Kropshofer H, Vogt AB, Thery C, Armandola EA, Li B-C, Moldenhauer G, A migorena S, Hämmerling GJ. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. EMBO J. 17:1998;2971-2981.
90. Karlsson L, Surh CD, Sprent J, Peterson PA. A novel class II MHC molecule with unusual tissue distribution. Nature. 351:1991;485-488.
91. Chang CH, Guerder S, Hong SC, van Ewijk W, Flavell RA. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity. 1996;167-178.
92. Denzin LK, Sant'Angelo DB, Hammond C, Surman MJ, Cresswell P. Negative regulation by HLA-DO of MHC class II-restricted antigen processing. Science. 278:1997;106-109.
93. van Ham SM, Tijn EPM, Lillemeier BF, Grüneberg U, van Meijgaarden KE, Pastoors L, Verwoerd D, Tulp A, Canas B, Rahman D, Ottenhoff THM, Pappin DJC, Trowsdale J, Neefjes J. HLA-DO is a negative modulator of HLA-DM mediated MHC class II peptide loading. Curr Biol. 7:1997;950-957.
94. Liljedahl M, Winqvist O, Surh CD, Wong P, Ngo K, Teyton IL, Peterson PA, Brunmark A, Rudensky AY, Fung-Leung W-P, Karlsson L. Altered antigen presentation in mice lacking H2-O. Immunity. 8:1998;233-243.
95. Vogt AB, Kropshofer H. HLA-DM - an endosomal/ lysosomal chaperone for the immune system. Trends Biochem Sci. 24:1999;150-154.
96. Ashton-Rickardt PG, Bandeira A, Delaney JR, Van Kaer L, Pircher HP, Z inkernagel RM, Tonegawa S. Evidence for a differential avidity model of T cell selection in the thymus. Cell. 76:1994;651-663.
97. Fukui Y, Hashimoto O, Inayoshi A, Gyotoku T, Sano T, Koga T, Gushima T, Sasazuki T. Highly restricted T cell repertoire shaped by a single major histocompatibility complex-peptide ligand in the presence of a single rearranged T cell receptor beta chain. J Exp Med. 188:1998;897-907.
98. Kasai M, Hirokawa K, Kajino K, Ogasawara K, Tatsumi M, Hermel E, Mona co JJ, Mizuochi T. Difference in antigen presentation pathways between cortical and medullary thymic epithelial cells. Eur J Immunol. 26:1996;2101-2107.
99. Douek DC, Altmann DM. HLA-DO is an intracellular class II molecule with distinctive thymic expression. Int Immunol. 9:1997;355-364.
100. Kasai M, Kominami E, Mizuochi T. The antigen presentation pathway in medullary thymic epithelial cells, but not that in cortical thymic epithelial cells, conforms to the endocytic pathway. Eur J Immunol. 28:1998;1867-1876.
101. Hammond C, Denzin LK, Pan M, Griffith JM, Geuze HJ, Cresswell P. The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules. J Immunol. 161:1998;3282-3291.
102. Lehner PJ, Trowsdale J. Coming out gracefully. Curr Biol. 8:1998.